Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration
Open Access
- 7 June 2007
- journal article
- clinical trial
- Published by Springer Nature in BMC Ophthalmology
- Vol. 7 (1) , 10
Abstract
To evaluate the efficacy of triple therapy consisting of single-session photodynamic therapy (PDT), intravitreal bevacizumab (IVB) and intravitreal triamcinolone (IVT) as initial pulse therapy followed by repeat intravitreal bevacizumab injections for maintenance treatment in neovascular age-related macular degeneration (AMD).Keywords
This publication has 30 references indexed in Scilit:
- COMBINED PHOTODYNAMIC THERAPY WITH VERTEPORFIN AND INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATIONRetina, 2006
- Triamcinolone acetonide suppresses early proangiogenic response in retinal pigment epithelial cells after photodynamic therapy in vitroBritish Journal of Ophthalmology, 2006
- Photodynamic therapy with verteporfin combined with intravitreal injection of bevacizumab for exudative age‐related macular degenerationActa Ophthalmologica Scandinavica, 2006
- Verteporfin and Intravitreal Triamcinolone Acetonide Combination Therapy for Occult Choroidal Neovascularization in Age-Related Macular DegenerationAmerican Journal of Ophthalmology, 2006
- Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age related macular degeneration: a comparative studyBritish Journal of Ophthalmology, 2006
- Intravitreal Triamcinolone Reinjection for Refractory Diabetic Macular EdemaKorean Journal of Ophthalmology, 2006
- Verteporfin Therapy Combined with Intravitreal Triamcinolone in All Types of Choroidal Neovascularization due to Age-Related Macular DegenerationOphthalmology, 2006
- Time Course and Morphology of Vascular Effects Associated with Photodynamic TherapyOphthalmology, 2005
- Problems with and pitfalls of photodynamic therapy 1 1The authors have no proprietary interest in this product.Ophthalmology, 2000
- Verteporfin photodynamic therapy retreatment of normal retina and choroid in the cynomolgus monkey11The Massachusetts Eye and Ear Infirmary is an owner of a patent covering the use of verteporfin and photodynamic therapy. Should the Massachusetts Eye and Ear Infirmary receive royalties or other financial remuneration related to that patent, Drs. Miller and Gragoudas would receive a share of same in accordance with the Massachusetts Eye and Ear Infirmary’s institutional Patent Policy and Procedures, which includes royalty-sharing provisions. As faculty members of the Harvard Medical School, they also adhere to their general Faculty Policies on Integrity in Science, which govern research and conflict of interest issues.Ophthalmology, 1999